Drugs / Varespladib
Varespladib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT05717062 | May 2023 → Nov 2024 | snakebite envenomation | Ophirex, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04969991 | Jun 2021 → Feb 2022 | COVID-19 | Ophirex, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00533039 | Oct 2007 → Jun 2009 | coronary artery disorder | University Health Network, Toronto | Completed | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01130246 | May 2010 → Mar 2012 | acute coronary syndrome | Anthera Pharmaceuticals | Terminated | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01522196 Comparator | Feb → Mar 2012 | sickle cell disease | Anthera Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Varespladib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00533039 ↗ |
| Known as | A-002 | “A-002 or Varespladib is an anti-inflammatory drug for treatment of chronic and acute diseases.” NCT00533039 ↗1“Drug: A-002, varespladib methyl” NCT01130246 ↗ |
| Known as | varespladib methyl | “Drug: A-002, varespladib methyl” NCT01130246 ↗ |
| Action | Inhibit | “treatment with varespladib, a small-molecule inhibitor of sPLA(2)” PMID 21098449 ↗ Nov 2010 |
| Modality | Small molecule | “treatment with varespladib, a small-molecule inhibitor of sPLA(2)” PMID 21098449 ↗ Nov 2010 |
| Route | Oral | “varespladib 500 mg PO BID” PMID 21098449 ↗ Nov 2010 |